Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s shares closed last Friday at $1.20. Discover the ...

On Tuesday, William Blair initiated coverage on Immunic Inc. (NASDAQ:IMUX) with an Outperform rating, highlighting the potential of its relapse-remitting multiple sclerosis (RMS) therapy ...

Fintel reports that on March 26, 2025, William Blair initiated coverage of StoneX Group (NasdaqGS:SNEX) with a Outperform recommendation. As of March 20, 2025, the average one-year price target ...

As of March 19, 2025, the average one-year price target for Immunic is $13.43/share. The forecasts range from a low of $5.05 to a high of $29.40. The average price target represents an increase of ...

On Tuesday, William Blair initiated coverage on Immunic Inc. (NASDAQ:IMUX) with an Outperform rating, highlighting the potential of its relapse-remitting multiple sclerosis (RMS) therapy, vidofludimus ...

Research analysts at William Blair initiated coverage on shares of Immunic (NASDAQ:IMUX – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set ...